Logo

Veracyte Signs an Exclusive License Agreement with NanoString for its nCounter FLEX System

Share this

Veracyte Signs an Exclusive License Agreement with NanoString for its nCounter FLEX System

Shots:

  • NanoString to receive $40M in cash & $10M in Veracyte’s stock along with $10M as milestones.  Veracyte to get an exclusive global right to develop and commercialize diagnostic tests on NanoString’s nCounter FLEX system
  • Veracyte will expand nCounter-based diagnostic portfolio utilizing its own test and has obtained rights to NanoString's 510(k)-cleared Prosigna breast cancer prognostic test and research-use LymphMark lymphoma assay and will distribute the nCounter FLEX system for diagnostic purposes
  • NanoString will retain an exclusive right to commercialize nCounter products and will manufacture test kits for Prosigna- LymphMark and new tests developed by Veracyte or its partners for use on the nCounter FLEX platform. Additionally- Veracyte will buy diagnostic assay kits and nCounter systems under a different supply agreement

Click here to­ read full press release/ article | Ref: Businesswire | Image: Owler


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions